Table 1 Frequency table summarizing the median and range and total number of important continuous and cathegorical clinicopathological variables, respectively.
From: High expression of microRNA-126 relates to favorable prognosis for colon cancer patients
Variable | n (%) | 5-y OS |
|---|---|---|
Age at diagnosis | ||
Median | 74.0 years (30–94 years) | N/A |
Tumor size | ||
Median | 50 mm (10–180 mm) | N/A |
Missing | 2 | N/A |
Gender | ||
Male | 209 (46.2%) | 59.8% |
Female | 243 (53.8%) | 62.1% |
Relapse | ||
No | 333 (73.7%) | 74.5% |
Yes | 119 (26.3%) | 23.5% |
pT status | ||
T1 | 9 (2.0%) | 88.9% |
T2 | 76 (16.8%) | 65.8% |
T3 | 320 (70.8%) | 61.6% |
T4a | 26 (5.8%) | 46.2% |
T4b | 21 (4.6%) | 42.9% |
pN status | ||
N0 | 291 (64.4%) | 68.4% |
N1a | 56 (12.4%) | 50.0% |
N1b | 55 (12.2%) | 52.7% |
N1c | 1 (0.2%) | 0% |
N2a | 27 (6.0%) | 40.7% |
N2b | 22 (4.9%) | 40.9% |
pTNM stage (groups) | ||
I | 72 (15.9%) | 70.8% |
II | 219 (48.5%) | 67.6% |
III | 161 (35.6%) | 47.8% |
Differentiation | ||
Well | 36 (8.0%) | 80.6% |
Moderate | 329 (72.8%) | 59.6% |
Poor | 75 (16.6%) | 60.0% |
Undifferentiated | 4 (0.9%) | 25.0% |
Missing | 8 (1.8%) | N/A |
Site | ||
Right | 227 (50.2%) | 63.0% |
Transverse | 65 (14.4%) | 49.2% |
Left | 21 (4.6%) | 66.7% |
Sigmoid | 136 (30.1%) | 61.8% |
Missing | 3 (0.7%) | N/A |
Weight loss | ||
< 10% | 248 (54.9%) | 68.5% |
≥ 10% | 94 (20.8%) | 46.8% |
Missing | 110 (24.3%) | N/A |
Performance status (ECOG) | ||
0 | 237 (52.4%) | 70.0% |
1 | 149 (33.0%) | 58.4% |
2 | 54 (11.9%) | 33.3% |
3 | 8 (1.8%) | 25.0% |
Missing | 4 (0.9%) | N/A |
Adjuvant chemotherapy | ||
No | 365 (80.8%) | 60.3% |
Yes | 87 (19.2%) | 67.8% |
Postoperative complications | ||
No | 358 (79.2%) | 64.5% |
Yes | 94 (20.8%) | 47.9% |
miR-126 expression tumor | ||
High | 140 (31.0%) | 67.9% |
Low | 300 (66.4%) | 58.0% |
Missing | 12 (2.7%) | N/A |
miR-126 expression stroma | ||
High | 109 (24.1%) | 63.3% |
Low | 341 (75.4%) | 60.4% |
Missing | 2 (0.4%) | N/A |
